首页> 美国卫生研究院文献>The British Journal of Ophthalmology >Prospective trial of intraoperative mitomycin C in the treatment of primary pterygium.
【2h】

Prospective trial of intraoperative mitomycin C in the treatment of primary pterygium.

机译:术中丝裂霉素C治疗原发性翼状ium肉的前瞻性试验。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIMS--A prospective, randomised, double blind, placebo controlled study of intraoperative mitomycin C as adjunctive treatment of primary pterygium was conducted. METHODS--A total of 66 eyes of 54 patients with primary pterygium were treated with excision, with or without a single intraoperative application of mitomycin C (0.1 mg/ml for 5 minutes) to evaluate the efficacy and toxicity of this adjunctive treatment. The mean follow up was 14.1 months (range 12-23 months). RESULTS--Of the 36 eyes that underwent simple excision, 14 (38.8%) exhibited recurrences whereas only one of 30 eyes (3.33%) treated with excision and intraoperative application of mitomycin C had recurrence (p = 0.0006). Neither serious ocular complications nor systemic toxicity were noted in the mitomycin C treated group. CONCLUSION--Intraoperative mitomycin C appears to be an effective and safe adjunctive treatment of primary pterygium.
机译:目的-对术中丝裂霉素C作为原发性翼状ium肉的辅助治疗进行前瞻性,随机,双盲,安慰剂对照研究。方法-对54例原发性翼状patients肉患者的66只眼进行了切除术,有无术中使用丝裂霉素C(0.1 mg / ml持续5分钟),以评估这种辅助治疗的疗效和毒性。平均随访14.1个月(范围12-23个月)。结果-在行简单切除的36眼中,有14例(38.8%)表现出复发,而经切除并术中应用丝裂霉素C治疗的30眼中只有1例(3.33%)复发(p = 0.0006)。在丝裂霉素C治疗组中,未发现严重的眼部并发症或全身毒性。结论:术中丝裂霉素C似乎是一种有效且安全的辅助治疗原发性翼状pt肉。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号